Jan. 26 at 3:32 PM
$TERN In case you missed it,
$TERN just silently did something that opens them up to add additional partnerships for their Leukemia drug, TERN-701. This from the article:
"Terns Pharmaceuticals has amended the licensing deal surrounding its closely watched leukemia drug. According to a regulatory filing made public Thursday, Terns acquired from China’s Hansoh Pharmaceutical the ability to license the drug, known as TERN-701 and in testing for chronic myeloid leukemia, in territories where Hansoh doesn’t have rights. Under the terms of a 2020 deal, Hansoh had to clear other partnering decisions. But for a
$1 million upfront payment and a small royalty, Terns can now seek other collaborations “without consent” from Hansoh, noted Mizuho Securities’ Graig Suvannavejh. The move should “clear the way for a potential partnership,” he added. TERN-701 is seen by some analysts as potentially disrupting the treatment landscape for CML. — Ben Fidler"
Here's the article:
https://www.biopharmadive.com/news/wegovy-pill-prescriptions-terns-deal-corcept-data-biomerieux/810253/
$XBI
